首页> 外文OA文献 >In Vitro Evaluation Of The Type Of Interaction Obtained By The Combination Of Terbinafine And Itraconazole, Voriconazole, Or Amphotericin B Against Dematiaceous Molds.
【2h】

In Vitro Evaluation Of The Type Of Interaction Obtained By The Combination Of Terbinafine And Itraconazole, Voriconazole, Or Amphotericin B Against Dematiaceous Molds.

机译:特比萘芬与伊曲康唑,伏立康唑或两性霉素B联合使用对皮肤病霉菌的相互作用类型的体外评估。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In vitro associations using the checkerboard microdilution method indicated lower MIC ranges and MIC median values for each drug (terbinafine, itraconazole, voriconazole, and amphotericin B) in association than those obtained for each single drug. Fractional inhibitory concentration index (FIC) results showed 100% synergism in the association of terbinafine with voriconazole, 96.5% in the association of terbinafine with amphotericin B, and 75.9% in the association of terbinafine with itraconazole. Drug combinations may be useful for treatment of dematiaceous mold infections as an alternative treatment to enhance the effectiveness of each drug.
机译:使用棋盘微量稀释法进行的体外联合表明,与每种药物相比,每种药物(特比萘芬,伊曲康唑,伏立康唑和两性霉素B)的MIC范围和MIC中值均较低。分数抑制浓度指数(FIC)结果显示,特比萘芬与伏立康唑的联用具有100%的协同作用,特比萘芬与两性霉素B的联结有96.5%的协同作用,特比萘芬与伊曲康唑的联结有75.9%的协同作用。药物组合可用于治疗皮肤病性霉菌感染,作为增强每种药物有效性的替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号